1. Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities.
- Author
-
Montecinos VP, Morales CH, Fischer TH, Burns S, San Francisco IF, Godoy AS, and Smith GJ
- Subjects
- Aged, Androgens pharmacology, Animals, Blood Platelets drug effects, Cell Adhesion drug effects, Endothelial Cells drug effects, Endothelial Cells metabolism, Freeze Drying, Human Umbilical Vein Endothelial Cells drug effects, Human Umbilical Vein Endothelial Cells metabolism, Humans, Male, Mice, Middle Aged, Optical Imaging, Prostate drug effects, Prostate pathology, Xenograft Model Antitumor Assays, Bioengineering methods, Blood Platelets metabolism, Prostatic Neoplasms blood supply
- Abstract
Androgen deprivation therapy (ADT) provides palliation for most patients with advanced prostate cancer (CaP); however, greater than 80% subsequently fail ADT. ADT has been indicated to induce an acute but transient destabilization of the prostate vasculature in animal models and humans. Human re-hydrated lyophilized platelets (hRL-P) were investigated as a prototype for therapeutic agents designed to target selectively the tumour-associated vasculature in CaP. The ability of hRL-P to bind the perturbed endothelial cells was tested using thrombin- and ADP-activated human umbilical vein endothelial cells (HUVEC), as well as primary xenografts of human prostate tissue undergoing acute vascular involution in response to ADT. hRL-P adhered to activated HUVEC in a dose-responsive manner. Systemically administered hRL-P, and hRL-P loaded with super-paramagnetic iron oxide (SPIO) nanoparticles, selectively targeted the ADT-damaged human microvasculature in primary xenografts of human prostate tissue. This study demonstrated that hRL-P pre-loaded with chemo-therapeutics or nanoparticles could provide a new paradigm for therapeutic modalities to prevent the rebound/increase in prostate vasculature after ADT, inhibiting the transition to castration-recurrent growth., (© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2015
- Full Text
- View/download PDF